Entering text into the input field will update the search result below

NGS Sample Preparation Market - Key Players Are Adopting Different Growth Strategies

Jan. 06, 2021 12:37 AM ETIllumina, Inc. (ILMN), TMO, QGEN, A, BDX
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Summary

  • Initiatives and Funding From Government & Private Bodies for Large-Scale Sequencing Projects.
  • Increasing Applications of NGS.

Global Leaders of the NGS Sample Preparation Industry:

Some of the prominent players in the NGS sample preparation market include Illumina Inc. (US), Thermo Fisher Scientific (US), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (US), Beckman Coulter (a subsidiary of Danaher), Becton, Dickinson and Company (BD) (US), Pacific Biosciences of California (US), PerkinElmer Inc. (US), F. Hoffmann-La Roche (Switzerland), and New England Biolabs, Inc. (US), among others.

Analysis of the developments in the NGS sample preparation market from 2016 to 2018 shows that product launches; agreements, partnerships and collaborations; expansions; and acquisitions were the most widely adopted growth strategies by players in the market. Players adopted these strategies to strengthen their market positions.

Illumina dominates the NGS market with its technologically advanced platforms and associated NGS products. The company’s product portfolio includes a wide range of highly interconnected products including sequencing, genotyping, gene expression, and molecular diagnostic products. The company also offers NGS services, which further strengthens its position in the market.

Thermo Fisher Scientific offers an extensive range of products, including analytical instruments, equipment, reagents & consumables, software & services for research, analysis, discovery, and diagnostics. In addition to a robust product portfolio of NGS sample preparation, the company has a substantial geographic presence. The company launched a number of products in the past three years, including the Oncomine Childhood Cancer Research Assay and the Oncomine Immune Response Research Assay.

Download PDF Brochure @ NGS Sample Preparation Market

What the Market Looks Like?

The NGS sample preparation market is projected to grow from USD 1.1 billion in 2019 to USD 2.7 billion by 2024, at a CAGR of 18.7% during the forecast period.

Major Growth Boosters:

Factors such as advancements in NGS platforms, reduced cost of sequencing, and improving reimbursement scenario for NGS-based diagnostic tests are driving the growth of this market. However, while the costs involved in NGS have reduced to some extent, they have not reached a level where broad adoption across developing markets can be achieved. This is a key restraint for market growth.

North America dominated the NGS sample preparation market in 2018

Geographically, the NGS sample preparation market is segmented into North America (US and Canada), Europe (Germany, France, the UK, and the Rest of Europe), Asia Pacific (China, Japan, India, and the Rest of Asia Pacific), and the Rest of the World (RoW). North America accounted for the largest share of the overall NGS sample preparation market in 2018 followed by Europe. The large share of North America can be attributed to the favorable initiatives by government and private bodies for the development and adoption of NGS technologies, wide adoption of NGS diagnostics in the region, increasing number of NGS-based research & clinical applications in the region, growing research on cancer, rising awareness of NGS services, and the presence of leading NGS service providers, in the region.

Talk to Our Experts for More Details@ NGS Sample Preparation Market

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.